Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
EDbxq3NnjP5xjwD0
Listen
